Clinical Pipeline Overview
Our innovative clinical pipeline focuses on cutting-edge therapeutics for solid and hematologic cancers, as well as autoimmune diseases. Below is an outline of the project candidates and their clinical development stages:
- GIC-102 (T.O.P. NK®):
- Target Disease: Solid and hematologic cancers.
- Current Stage: Phase 2a.
- Description: An advanced NK cell-based therapy, optimized for targeting a broad spectrum of cancer types with enhanced precision and efficacy.
- GIC-101 (Nano NK®):
- Target Disease: Solid cancers.
- Current Stage: Preclinical.
- Description: Nano-engineered NK cell therapy designed for maximum therapeutic activity and efficient delivery to solid tumor sites.
- GIC-302 (Drone Treg®):
- Target Disease: Inflammatory Bowel Disease.
- Current Stage: Preclinical.
- Description: A regulatory T-cell-based therapy aimed at modulating immune responses to restore balance in autoimmune diseases.
- CAR NK Therapy:
- Target Disease: Solid and hematologic cancers.
- Current Stage: Preclinical.
- Description: CAR-modified NK cells engineered for enhanced tumor recognition and destruction, addressing unmet needs in oncology.
This robust pipeline highlights our commitment to pioneering therapies that address critical medical challenges in cancer and autoimmune conditions. Each program is designed with patient-specific needs and advanced technologies to ensure safety and efficacy.